康希諾生物(06185.HK):DTcP-Hib-MCV4聯合疫苗在中國獲臨牀試驗批準
格隆匯2月24日丨康希諾生物(06185.HK)宣佈,公司研發的吸附無細胞百(組分)白破("DTcP")b型流感嗜血桿菌(結合)("Hib")-ACYW135羣腦膜炎球菌(結合)("MCV4")聯合疫苗("DTcPHib-MCV4聯合疫苗")已獲得中華人民共和國國家藥品監督管理局批準,可以開展相關臨牀試驗。
於公告日期,作爲DTcP-Hib-MCV4聯合疫苗的組成部分,公司的國內首個腦膜炎球菌四價結合疫苗產品曼海欣®已獲得藥品註冊證書並商業化,嬰幼兒用DTcP處於III期臨牀階段,Hib疫苗處於I期臨牀階段。基於上述疫苗開發過程中所累積的相關數據,公司擬研發DTcP-Hib-MCV4聯合疫苗,滿足市場對多聯疫苗的需求,並形成差異化競爭。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.